Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market CAGR Outlook And Future Development
The messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market has experienced rapid expansion in recent years. This market is projected to grow from $39.69 billion in 2025 to $45.88 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.6%. Historically, this growth can be attributed to factors such as COVID-19 vaccine breakthroughs, prior viral vector research, global pandemic preparedness programs, advances in genomic sequencing, and early nucleic acid vaccine trials.
The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market size is anticipated to undergo significant expansion in the upcoming years. It is projected to achieve a valuation of $82.61 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 15.8%. The observed growth within the forecast period can be ascribed to several factors, including the proliferation of personalized cancer vaccines, the expansion of infectious disease pipelines, swifter platform-based approvals, an increase in biotech funding, and broader utilization of therapeutic vaccines. Prominent trends emerging in the forecast period encompass self-amplifying mrna platforms, optimization of lipid nanoparticle delivery, modular vaccine platform design, rapid adaptation to pathogen targets, and innovative next-generation adjuvant systems.
Get A Free Sample Report With In-Depth Market Insights:
Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Growth Factors: What’s Supporting Expansion?
The increasing need for personalized medical solutions is anticipated to drive the expansion of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market moving forward. Personalized medicine defines a healthcare approach where disease prevention and treatment strategies are specifically crafted based on an individual’s genetic makeup, molecular traits, and particular health conditions. The escalating demand for personalized medicine arises from the rising prevalence of complex and chronic diseases, as these conditions necessitate targeted and patient-specific therapeutic options to enhance treatment effectiveness and safety outcomes. Messenger ribonucleic acid (mRNA) and next-generation vaccine platforms empower personalized medicine by allowing for swift, adaptable, and highly specific vaccine and therapeutic designs that can be tailored to individual genetic and disease profiles, thus supporting precision-based healthcare delivery. For instance, in February 2024, information from the Personalized Medicine Coalition, a US-based hospital and health care organization, indicated that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, which was an increase from six in 2022. Therefore, the growing demand for personalized medicine is propelling the growth of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market.
Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Segment Breakdown: Which Categories Lead On Revenue?
The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market covered in this report is segmented –
1) By Vaccine Type: Messenger Ribonucleic Acid Vaccines; Deoxyribonucleic Acid (DNA) Vaccines; Viral Vector Vaccines; Protein Subunit Vaccines; Peptide Vaccines; Other Vaccine Types
2) By Technology or Platform: Lipid Nanoparticle (LNP) Delivery; Self-Amplifying Messenger Ribonucleic Acid; Circular Messenger Ribonucleic Acid; Replicon or Non-replicating Platforms; Viral Vector Technologies
3) By Disease Indication: Infectious Diseases; Oncology; Rare Diseases; Other Disease Indications
4) By End User: Pharmaceutical and Biotechnology Companies; Contract Research Organizations (CROs); Academic and Research Institutes; Hospitals and Clinics
Subsegments:
1) By Messenger Ribonucleic Acid Vaccines: Conventional Messenger Ribonucleic Acid Vaccines; Self Amplifying Messenger Ribonucleic Acid Vaccines; Modified Messenger Ribonucleic Acid Vaccines; Circular Messenger Ribonucleic Acid Vaccines
2) By Deoxyribonucleic Acid Vaccines: Plasmid Deoxyribonucleic Acid Vaccines; Viral Assisted Deoxyribonucleic Acid Vaccines; Synthetic Deoxyribonucleic Acid Vaccines; Gene Based Deoxyribonucleic Acid Vaccines
3) By Viral Vector Vaccines: Adenovirus Based Viral Vector Vaccines; Lentivirus Based Viral Vector Vaccines; Poxvirus Based Viral Vector Vaccines; Measles Virus Based Viral Vector Vaccines
4) By Protein Subunit Vaccines: Recombinant Protein Vaccines; Virus Like Particle Vaccines; Toxoid Based Protein Vaccines; Polysaccharide Conjugate Vaccines
5) By Peptide Vaccines: Synthetic Peptide Vaccines; Personalized Peptide Vaccines; Multi Epitope Peptide Vaccines; Long Peptide Vaccines
6) By Other Vaccine Types: Protein Subunit Vaccines, Virus-Like Particle Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vector Vaccines
Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Industry Trends: What’s Reshaping Demand?
Major companies operating in the mRNA and next-generation vaccine platforms market are concentrating on developing advanced mRNA-based COVID-19 vaccines to improve immune persistence, expand variant coverage, and enhance overall vaccine performance. These next-generation mRNA COVID-19 vaccines leverage sophisticated mRNA engineering and delivery technologies to provide broader and more enduring protection against existing and emerging SARS-CoV-2 variants. They also aim to boost safety, stability, and storage convenience while enabling swift adaptation to viral evolution. For instance, in June 2025, Moderna Inc., a US-based biotechnology company, unveiled mNEXSPIKE, its next-generation COVID-19 vaccine, crafted to strengthen protection against circulating and emerging SARS-CoV-2 variants. This vaccine incorporates an updated spike protein antigen that more closely aligns with recent variants and seeks to deliver improved immune durability and effectiveness, supporting ongoing COVID-19 prevention initiatives and future booster strategies.
Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Competitive Overview And Top Companies
Major companies operating in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Moderna Inc., BioNTech SE, Novavax Inc., Walvax Biotechnology Co Ltd, Arcturus Therapeutics Inc, Gennova Biopharmaceuticals Ltd, Vaxxas Pty Ltd, Vaxart Inc, Ethris GmbH, The Biologicals and Vaccines Institute of Southern Africa Proprietary Limited, eTheRNA Immunotherapies NV, Stemirna Therapeutics Co Ltd, Primrose Bio Inc, Acuitas Therapeutics Inc, and Incepta Vaccine Ltd.
View The Full Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Report:
Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Leading Geography: Which Region Contributes The Most Revenue?
North America was the largest region in the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model